ARTICLE SUMMARY:
Renal denervation is once again under pressure as both Medtronic and ReCor deal with recent clinical trial setbacks. These new hurdles highlight the continuing challenges of RDN trials and raise questions about future market acceptance.
After experiencing something of a rebirth over the past few years, renal denervation (RDN) is once again facing some hard questions in the wake of recent clinical trial disappointments. These new speedbumps highlight the many challenges of conducting device trials for the treatment of high blood pressure as well as the limitations of existing RDN technology.
